Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06921785 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
A Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,220
- Enrollment target
- 20
- Study locations
NCT06921785: Recruiting Phase 3 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
NCT06921785 is a Phase 3 study of Hepatocellular Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,220 participants, above the 249-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (390% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06921785, a Phase 3 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Primary Outcome
OS is defined as the time from randomisation until the date of death due to any cause.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Rilvegostomig
- DRUG Tremelimumab
Study Locations (20)
New York
- Research Site - New York
- Research Site - New York
- Research Site - New York
Arizona
- Research Site - Phoenix
- Research Site - Tucson
California
- Research Site - Palo Alto
- Research Site - Santa Monica
Georgia
- Research Site - Atlanta
- Research Site - Fayetteville
Michigan
- Research Site - Detroit
- Research Site - Grand Rapids
Connecticut
- Research Site - New Haven
Delaware
- Research Site - Newark
Florida
- Research Site - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,220 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2030-03-14 |
| Phase | Phase 3 |
What NCT06921785 shows while recruiting
NCT06921785 is an interventional study that assigns participants to a tested intervention. Its 1,220 participants enrollment target places it among the larger protocols in the corpus, above the 249-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (390% higher).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT06921785 names 20 study sites across 14 states, led by New York, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06921785 about?
NCT06921785 is a clinical study titled "Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma". This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in par...
What is the current status of trial NCT06921785?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,220 participants. The study started on 2025-05-06. Estimated completion is 2030-03-14.
What conditions does trial NCT06921785 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06921785?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Rilvegostomig (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT06921785?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06921785 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06921785's enrollment target sits among peer trials
1,220 7th of 145 higher than 139 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
-
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI